SG11201701704XA - Compositions and methods for treating proliferation disorders - Google Patents
Compositions and methods for treating proliferation disordersInfo
- Publication number
- SG11201701704XA SG11201701704XA SG11201701704XA SG11201701704XA SG11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA SG 11201701704X A SG11201701704X A SG 11201701704XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- proliferation disorders
- treating proliferation
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046502P | 2014-09-05 | 2014-09-05 | |
| US201462082236P | 2014-11-20 | 2014-11-20 | |
| PCT/US2015/048520 WO2016037044A1 (en) | 2014-09-05 | 2015-09-04 | Compositions and methods for treating proliferation disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701704XA true SG11201701704XA (en) | 2017-04-27 |
Family
ID=55436479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701704XA SG11201701704XA (en) | 2014-09-05 | 2015-09-04 | Compositions and methods for treating proliferation disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9949981B2 (https=) |
| EP (1) | EP3189036B1 (https=) |
| JP (2) | JP6574245B2 (https=) |
| KR (1) | KR20170045748A (https=) |
| CN (2) | CN111494378A (https=) |
| AU (2) | AU2015311751B2 (https=) |
| BR (1) | BR112017004459A2 (https=) |
| CA (1) | CA2958770A1 (https=) |
| ES (1) | ES2955926T3 (https=) |
| IL (2) | IL250715B (https=) |
| MX (1) | MX382891B (https=) |
| RU (2) | RU2019142694A (https=) |
| SG (1) | SG11201701704XA (https=) |
| WO (1) | WO2016037044A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11561226B2 (en) | 2016-03-14 | 2023-01-24 | Pierce Biotechnology Inc. | Detection and quantification of AKT-mTOR pathway proteins |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| US20190350929A1 (en) * | 2017-02-02 | 2019-11-21 | Epizyme, Inc. | Cancer treatment modalities |
| WO2019071171A1 (en) * | 2017-10-05 | 2019-04-11 | The Board Of Trustees Of The University Of Illinois | Method of treating sickle cell disease |
| CN110669015A (zh) * | 2018-07-03 | 2020-01-10 | 上海喀露蓝科技有限公司 | 一种fgfr抑制剂的制备方法 |
| EP3880202A2 (en) * | 2018-11-16 | 2021-09-22 | ArQule, Inc. | Pharmaceutical combination for treatment of cancer |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| PL3919491T3 (pl) * | 2019-01-29 | 2025-10-20 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor akt |
| US20220184147A1 (en) * | 2019-03-04 | 2022-06-16 | Northwestem University | Bacterial enzymatic conversion of anthracycline chemotherapeutics to reduce toxicity and promote diversity among the intestinal microbiota |
| WO2022053708A1 (en) * | 2020-09-14 | 2022-03-17 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma |
| IL301567A (en) * | 2020-09-30 | 2023-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | A compound as an AKT KINASE inhibitor |
| CN112225745B (zh) * | 2020-11-16 | 2021-10-12 | 烟台大学 | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 |
| EP4486390A1 (en) * | 2022-03-02 | 2025-01-08 | Terremoto Biosciences, Inc | Covalent modifiers of akt1 and uses thereof |
| WO2025034613A1 (en) * | 2023-08-04 | 2025-02-13 | Terremoto Biosciences, Inc. | 3h-imidazo[4,5-b]pyridine compounds as non-covalent modifiers of akt1 and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010078430A1 (en) * | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
| TWI461410B (zh) * | 2008-12-30 | 2014-11-21 | Arqule Inc | 經取代之５，６－二氫－６－苯基苯並〔f〕異喹啉－２－胺化合物類 |
| EP2414358A1 (en) * | 2009-03-31 | 2012-02-08 | ArQule, Inc. | Substituted tetrahydropyrazolo-pyrido-azepin compounds |
| DK2519522T3 (en) * | 2009-12-30 | 2014-12-08 | Arqule Inc | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS |
| KR20190015600A (ko) | 2011-06-24 | 2019-02-13 | 아르퀼 인코포레이티드 | 치환된 이미다조피리디닐-아미노피리딘 화합물 |
| US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
-
2015
- 2015-09-04 EP EP15838638.3A patent/EP3189036B1/en active Active
- 2015-09-04 AU AU2015311751A patent/AU2015311751B2/en not_active Ceased
- 2015-09-04 BR BR112017004459A patent/BR112017004459A2/pt not_active IP Right Cessation
- 2015-09-04 RU RU2019142694A patent/RU2019142694A/ru unknown
- 2015-09-04 WO PCT/US2015/048520 patent/WO2016037044A1/en not_active Ceased
- 2015-09-04 CN CN202010227563.XA patent/CN111494378A/zh active Pending
- 2015-09-04 KR KR1020177008846A patent/KR20170045748A/ko not_active Abandoned
- 2015-09-04 CN CN201580060093.XA patent/CN107074769B/zh not_active Expired - Fee Related
- 2015-09-04 JP JP2017512759A patent/JP6574245B2/ja not_active Expired - Fee Related
- 2015-09-04 CA CA2958770A patent/CA2958770A1/en not_active Abandoned
- 2015-09-04 ES ES15838638T patent/ES2955926T3/es active Active
- 2015-09-04 US US14/845,795 patent/US9949981B2/en active Active
- 2015-09-04 MX MX2017002892A patent/MX382891B/es unknown
- 2015-09-04 RU RU2017111204A patent/RU2711500C2/ru active
- 2015-09-04 SG SG11201701704XA patent/SG11201701704XA/en unknown
-
2017
- 2017-02-22 IL IL250715A patent/IL250715B/en active IP Right Grant
-
2019
- 2019-08-15 JP JP2019149011A patent/JP6837525B2/ja not_active Expired - Fee Related
-
2020
- 2020-06-04 AU AU2020203706A patent/AU2020203706B2/en not_active Expired - Fee Related
- 2020-08-31 IL IL277028A patent/IL277028A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111494378A (zh) | 2020-08-07 |
| WO2016037044A1 (en) | 2016-03-10 |
| CN107074769A (zh) | 2017-08-18 |
| ES2955926T3 (es) | 2023-12-11 |
| MX2017002892A (es) | 2017-06-06 |
| RU2711500C2 (ru) | 2020-01-17 |
| MX382891B (es) | 2025-03-13 |
| IL250715B (en) | 2020-09-30 |
| EP3189036B1 (en) | 2023-07-19 |
| RU2017111204A (ru) | 2018-10-05 |
| AU2020203706B2 (en) | 2022-01-13 |
| BR112017004459A2 (pt) | 2017-12-05 |
| CA2958770A1 (en) | 2016-03-10 |
| RU2019142694A (ru) | 2020-02-26 |
| AU2015311751A1 (en) | 2017-03-09 |
| IL277028A (en) | 2020-10-29 |
| KR20170045748A (ko) | 2017-04-27 |
| JP6837525B2 (ja) | 2021-03-03 |
| US20160067260A1 (en) | 2016-03-10 |
| EP3189036A4 (en) | 2018-04-04 |
| RU2017111204A3 (https=) | 2019-03-25 |
| EP3189036A1 (en) | 2017-07-12 |
| IL250715A0 (en) | 2017-04-30 |
| JP2017526698A (ja) | 2017-09-14 |
| AU2020203706A1 (en) | 2020-06-25 |
| AU2015311751B2 (en) | 2020-03-12 |
| CN107074769B (zh) | 2020-04-07 |
| US9949981B2 (en) | 2018-04-24 |
| JP6574245B2 (ja) | 2019-09-11 |
| JP2020002148A (ja) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
| IL251721A0 (en) | Preparations and methods for the treatment of diseases of the central nervous system | |
| IL250715A0 (en) | Preparations and methods for the treatment of cultural disorders | |
| SMT202000414T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
| SMT202000276T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
| AP2017009674A0 (en) | Methods and compositions for treating ulcers | |
| IL251759A0 (en) | Preparations and methods for treating insomnia | |
| PT3200815T (pt) | Métodos e composições para o tratamento de cancro | |
| LT3189074T (lt) | Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai | |
| IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
| EP3126004A4 (en) | Methods and compositions for treating inflammatory disorders | |
| EP3134120A4 (en) | Compositions and methods for treating cytokine-related disorders | |
| EP3142699A4 (en) | Compositions and methods for treating metabolic disorders | |
| IL251616A0 (en) | Methods and compounds for the treatment and prevention of muscle loss | |
| ZA201703771B (en) | Compositions and methods for treating hyperkalemia | |
| IL253220A0 (en) | Preparations and methods for the treatment of glaucoma | |
| IL250114A0 (en) | Methods and compositions for the treatment of hiv-related diseases | |
| ZA201605109B (en) | Compositions and methods for treating neutropenia | |
| EP3262065A4 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
| IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
| IL252707B (en) | Compositions and methods for treating diseases | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof | |
| HK1242518A1 (en) | Compositions and methods for treating cns disorders | |
| GB201407949D0 (en) | Compositions and methods for treating biofilms |